Triamcinolone ophthalmic

Do not receive a smallpox vaccine or any other "live" vaccine if you are being treated long-term with triamcinolone ophthalmic. Some vaccines may not work as well during treatment with steroid medicine at certain doses. Some vaccines may even cause dangerous side effects when used during steroid treatment. Before you receive any vaccine, talk with the doctor who is treating you with triamcinolone ophthalmic.

Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroids.

Usual Adult Dose for Uveitis:

4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment

Comments:
-Strict aseptic technique is mandatory.
-The vial should be vigorously shaken for 10 seconds before use.
-Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
-After withdrawal, the suspension should be injected without delay.
-Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Uses:
-Treatment of sympathetic ophthalmia
-Treatment of temporal arteritis
-Treatment of uveitis
-Treatment of ocular inflammatory conditions unresponsive to topical

Usual Adult Dose for Temporal Arteritis:

4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment

Comments:
-Strict aseptic technique is mandatory.
-The vial should be vigorously shaken for 10 seconds before use.
-Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
-After withdrawal, the suspension should be injected without delay.
-Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Uses:
-Treatment of sympathetic ophthalmia
-Treatment of temporal arteritis
-Treatment of uveitis
-Treatment of ocular inflammatory conditions unresponsive to topical

Usual Adult Dose for Vitrectomy:

1 to 4 mg (25 to 100 microliters of 40 mg/mL suspension) administered intravitreally

Comments:
-Strict aseptic technique is mandatory.
-The vial should be vigorously shaken for 10 seconds before use.
-Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
-After withdrawal, the suspension should be injected without delay.
-Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Use: Visualization during vitrectomy

Usual Pediatric Dose for Uveitis:

4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment

Comments:
-Strict aseptic technique is mandatory.
-The vial should be vigorously shaken for 10 seconds before use.
-Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
-After withdrawal, the suspension should be injected without delay.
-Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Uses:
-Treatment of sympathetic ophthalmia
-Treatment of temporal arteritis
-Treatment of uveitis
-Treatment of ocular inflammatory conditions unresponsive to topical

Usual Pediatric Dose for Temporal Arteritis:

4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment

Comments:
-Strict aseptic technique is mandatory.
-The vial should be vigorously shaken for 10 seconds before use.
-Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
-After withdrawal, the suspension should be injected without delay.
-Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Uses:
-Treatment of sympathetic ophthalmia
-Treatment of temporal arteritis
-Treatment of uveitis
-Treatment of ocular inflammatory conditions unresponsive to topical

Usual Pediatric Dose for Vitrectomy:

1 to 4 mg (25 to 100 microliters of 40 mg/mL suspension) administered intravitreally

Comments:
-Strict aseptic technique is mandatory.
-The vial should be vigorously shaken for 10 seconds before use.
-Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
-After withdrawal, the suspension should be injected without delay.
-Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Use: Visualization during vitrectomy

• If you need to store this medicine at home, talk with your child's doctor, nurse, or pharmacist about how to store it.

• If your symptoms or health problems do not get better or if they become worse, call your doctor.
• Do not share your drugs with others and do not take anyone else's drugs.
• Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
• Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.
• Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
• Check with your pharmacist about how to throw out unused drugs.
• Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about triamcinolone, please talk with your doctor, nurse, pharmacist, or other health care provider.
• If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about triamcinolone (ophthalmic). It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using triamcinolone.

Review Date: October 4, 2017

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Suspension, Intraocular, as acetonide:

Triesence: 40 mg/mL (1 mL) [contains polysorbate 80]

Suppresses the immune system by reducing activity and volume of the lymphatic system

Half-Life Elimination

Intravitreal: Nonvitrectomized patients: 18.7 ± 5.7 days; Vitrectomized patients: ~3.2 days (based upon 1 patient)

Hypersensitivity to triamcinolone or any component of the formulation; systemic fungal infections

Canadian labeling: Additional contraindications (not in US labeling): Active ocular herpes simplex

Ocular disease: Intravitreal: Initial: 4 mg as a single dose; additional doses may be given as needed

Visualization during vitrectomy: Intravitreal: 1 to 4 mg

Vitrectomy: May be diluted with sterile irrigating solution (eg, BSS Sterile Irrigating Solution) prior use. Range of dilution is typically 1:10 to 1: 20. In a clinical study, a 2 mg/mL was administered by diluting 0.05 mL of triamcinolone in 0.95 mL of sterile irrigating solution (Triesence Canadian product labeling 2016).

Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. Monitor therapy

NSAID (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. Monitor therapy

Adverse events were have been observed in animal reproduction studies. Some studies have shown an association between first trimester corticosteroid use and oral clefts, intrauterine growth restriction, and decreased birth weight. The amount of triamcinolone absorbed systemically following ophthalmic administration is not known. Use of intravitreal triamcinolone in pregnancy has been noted in case reports (Errera 2013; Fazelat 2011).

1 to 4 mg (25 to 100 microliters of 40 mg/mL suspension) administered intravitreally

Comments:
-Strict aseptic technique is mandatory.
-The vial should be vigorously shaken for 10 seconds before use.
-Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration).
-After withdrawal, the suspension should be injected without delay.
-Careful technique should be employed to avoid the possibility of entering a blood vessel or introducing organisms that can cause infection.

Use: Visualization during vitrectomy